The main point I was trying to make about the unblinding of data relating to efficacy from the DARRT-2 trial was to do with controlling the type I error rate. Although it is an adaptive Phase2/3 trial, I presume NOX will still need to control the type I error rate if they choose to unblind the data in order to provide confirmatory evidence of efficacy at the final analysis. Unless NOX expect to make the appropriate adjustments to their sample size and/or treatment selection for the confirmatory trial (as you've mentioned), but NOX hasn't yet made that information public.
I've taken onboard and agree with your comments about the IONIC study.
- Forums
- ASX - By Stock
- NOX
- Strategy
Strategy, page-7
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.14M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 11.0¢ | $6.05K | 55K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 154466 | 11.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 216870 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 154466 | 0.110 |
2 | 44047 | 0.105 |
5 | 89611 | 0.100 |
1 | 186361 | 0.098 |
2 | 306000 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 216870 | 2 |
0.120 | 167346 | 6 |
0.125 | 164133 | 6 |
0.130 | 409378 | 5 |
0.135 | 205000 | 2 |
Last trade - 10.10am 17/10/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online